Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 18, Issue 8, Pages 889-901Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543776.18.8.889
Keywords
EGFR; HER; monoclonal antibody; targeted therapy; tyrosine kinase inhibitor
Categories
Ask authors/readers for more resources
Background: The 'targeted therapy' has been defined as an innovative therapy designed to interfere with molecular targets playing a critical role in tumour growth or progression. The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor mediating the effect of growth factors both in physiological and pathological conditions; aberrations in the EGFR may result in the development of a tumour phenotype. Objective: To summarise the current state of the development of anti-EGFR drugs. Methods: Patent literature and preclinical/clinical studies about EGFR inhibitors are analysed. Conclusion: Some monoclonal antibodies and small-molecule tyrosine kinase inhibitors have been approved in several countries for the treatment of various human cancer types; moreover, more than ten EGFR-targeting agents are actually in advanced clinical development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available